Target intelligence / Profile preview

Pseudogene similar to part of cell division cycle 42 (CDC42)

Molecular classification
Other (Pseudogene)
01

Overview

ENSG00000225018 is a **pseudogene** related in sequence to the CDC42 gene (cell division cycle 42, a small GTPase involved in cell cycle and cytoskeleton organization)[2]. Pseudogenes are genomic elements that resemble protein-coding genes but are generally non-functional due to accumulated mutations—most do not encode proteins, nor do they have normal gene regulatory functions[3][6][7]. While some pseudogenes can impact gene regulation at the DNA, RNA, or even peptide level, there is no evidence in the provided sources that this specific pseudogene has a defined functional role, biomarker utility, therapeutic targeting potential, or involvement in disease mechanisms beyond generic pseudogene biology[2][3][6][7]. ### Essential context and interpretation: - ENSG00000225018 is explicitly classified as a pseudogene, not a protein-coding gene, enzyme, receptor, transporter, or other canonical pharmacological target class[2]. - Pseudogenes can sometimes regulate their “parent” gene’s expression through noncoding RNA mechanisms or act as competitive endogenous RNAs (ceRNAs), but this is not universally the case and is not specifically described for this locus[6][7]. - As a pseudogene, it is **not associated with any known small-molecule or biologic drugs**, and there are no defined therapeutic mechanisms or clinical biomarkers[2]. - Biological and disease roles for this locus are generic to pseudogene biology; there is no direct implication in disease per current knowledge for this locus. Some pseudogenes in general may impact cancer biology or gene regulation, but this has not been specifically shown or cited for ENSG00000225018[3][6][7]. - **is_incorrect** is true because this locus is not a druggable target or receptor and lacks molecular or therapeutic relevance as required for a canonical “target molecule/receptor.” It is included for completeness but does not meet criteria for a pharmacological or clinical target. ### Summary ENSG00000225018 is a non-functional **pseudogene** related to CDC42; it is not a druggable target, and there is no evidence of direct functional, therapeutic, or biomarker significance at this time[2][3][6][7]. If information about the **functional CDC42 gene or protein** is needed, that locus is different and recognized as a canonical molecular target in genetics and cell biology[1][4][5].

Other names
Pseudogene similar to part of CDC42ENSG00000225018
02

Biological functions

Other (see context below)
03

Disease associations

Other (see context below)

Beyond the preview

Go deeper on Pseudogene similar to part of cell division cycle 42 (CDC42).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pseudogene similar to part of cell division cycle 42 (CDC42).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call